Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.56 |
| ▸ | APAF1 | O14727 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | ALPL | P05186 | 2/20 | 0.55 |
| ▸ | ALPG | P10696 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | ALPI | P09923 | 1/20 | 0.55 |
| ▸ | PLAA | Q9Y263 | 1/20 | 0.55 |
| ▸ | CDYL2 | Q8N8U2 | 1/20 | 0.53 |
| ▸ | CDYL | Q9Y232 | 1/20 | 0.53 |
| ▸ | CDY1; CDY1B | Q9Y6F8 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10881570 | 0.83 | KDM4E (0.65) | KDM4ENPC1EGLN3APAF1TDP1 | |
| SCHEMBL1035783 | 0.81 | EGLN3 (0.71) | KDM4ENPC1EGLN3APAF1TDP1 | |
| SCHEMBL7404412 | 0.80 | ALDH1A1 (0.65) | KDM4ENPC1TDP1SMN1; SMN2LMNA | |
| SCHEMBL3041706 | 0.80 | EGLN3 (0.60) | KDM4ENPC1EGLN3APAF1TDP1 | |
| SCHEMBL11982379 | 0.80 | SMN1; SMN2 (0.66) | KDM4ENPC1TDP1SMN1; SMN2LMNA | |
| SCHEMBL1038315 | 0.80 | KDM4E (0.69) | KDM4ENPC1EGLN3APAF1TDP1 | |
| Hydrogen Sulfide SCHEMBL28767930 | 0.80 | EGLN3 (0.69) | KDM4ENPC1EGLN3APAF1TDP1 | |
| SCHEMBL11460254 | 0.80 | KDM4E (0.65) | KDM4ENPC1EGLN3APAF1TDP1 | |
| Hydrochloric Acid SCHEMBL1082612 | 0.80 | EGLN3 (0.69) | KDM4ENPC1EGLN3APAF1TDP1 | |
| SCHEMBL27864830 | 0.80 | TDP1 (0.63) | KDM4ENPC1EGLN3APAF1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382946-A1 | POLYPEPTIDE OR PROTEIN DIRECTIONAL MODIFICATION METHOD BASED ON SULFHYDRYL-ALKENYL AZIDE COUPLING | Changzhou University (CN) | 2023-11-30 | — | — | US | disclosed |
| US-20090176831-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | OSTA BIOTECHNOLOGIES (CA) | 2009-07-09 | — | — | US | disclosed |
| US-7482469-B2 | 2-(benzimidazol-1-yl)-acetamide bisaryl derivatives | N.V. ORGANON (NL) | 2009-01-27 | — | — | US | disclosed |
| US-20070112034-A1 | 2-(benzimidazol-1-yl)-acetamide bisaryl derivatives | AKZO NOBEL N.V. (NL) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382946-A1 | POLYPEPTIDE OR PROTEIN DIRECTIONAL MODIFICATION METHOD BASED ON SULFHYDRYL-ALKENYL AZIDE COUPLING | PTMS, CBS, CHAMP1 | KDM4E 4700/4885NPC1 4725/4885EGLN3 3194/4885 |
| US-20070112034-A1 | 2-(benzimidazol-1-yl)-acetamide bisaryl derivatives | TRPV1, TRPV3, TRPV2 | KDM4E 4243/4885NPC1 387/4885EGLN3 988/4885 |
| US-20090176831-A1 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System | HMOX1, HMOX2, CYC1 | KDM4E 4294/4885NPC1 708/4885EGLN3 348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.